Abstract OBJECTOVE: Early response to therapy is one of the most important prognostic factors in childhood acute lymphoblastic leukemia (ALL). This study aimed to assess the prognostic value of morphological assessment of bone marrow blasts during remission induction and determination of minimal residual disease (MRD) after remission induction. METHODS: From January 1998 to May 2003, 193 children with newly diagnosed ALL were enrolled on the ALL-XH-99 protocol. Blast cell count in the bone marrow was examined on day 19 of remission induction and by the completion of remission induction. MRD was measured with the flow cytometry. Event-free survival (EFS) was estimated by Kaplan-Meier analysis and the distributions of EFS were compared using the log-rank test. A Cox proportional hazards model was used to identify independent prognostic factors. RESULTS: The 4-year EFS was significantly worse in patients with ≥ 5% lymphoblasts in the bone marrow on day 19 as compared to those with <5% lymphoblasts on that date (42.59%±14.28% vs 74.24%±6.67%; P<0.01). The 4-year EFS was significantly worse in patients with any amount of lymphoblasts in the bone marrow on the remission date as compared to that of other patients with no morphologically identifiable blasts (63.47%±9.23% vs 76.41%±6.09%; P<0.05). The patients with MRD <0.01 had significantly better outcome than those with a level ≥ 0.01% (15-month EFS:94.44%±5.40% vs 23.81%±20.26%; P<0.01). CONCLUSIONS: Early treatment response as assessed by morphological examination or minimal residual leukemia determination by flow cytometry has important prognostic significance, and can be performed in a resource-poor patient population.［Chin J Contemp Pediatr, 2008, 11 (1):5-9］
TIE Li-Jun,GU Long-Jun,SONG De-Lian et al. Prognostic value of early treatment response in childrenwith acute lymphoblastic leukemia: a single institution experience in Shanghai, China[J]. 中国当代儿科杂志, 2009, 11(01): 5-9.
TIE Li-Jun,GU Long-Jun,SONG De-Lian et al. Prognostic value of early treatment response in childrenwith acute lymphoblastic leukemia: a single institution experience in Shanghai, China[J]. CJCP, 2009, 11(01): 5-9.
［3］Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995［J］. Leukemia, 2000, 4(12): 2223-2233.
［4］Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995［J］. Leukemia, 2000, 14(12):2205-2222.
［5］Schrappe M, Reiter A, Ludwig WD, Harbott J, Zimmermann M, Hiddemann W, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90［J］. Blood, 2000, 95(11): 3310-3322.
［6］Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT, et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia［J］. Blood, 1995, 86(4):1292-1295.
［7］Pui CH, Compana D. New definition of remission in childhood acute lymphoblastic leukemia［J］. Leukemia, 2000, 14(5):783-785.
［8］van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L, et al. Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia［J］. Lancet, 1998, 352(9142):1731-1738.
［9］Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, et al. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia［J］. Blood, 2000, 96(8): 2691-2696.
［10］Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, et al. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia［J］. Leukemia, 2008, 22(4):771-782.
［11］Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study［J］. Blood, 2008, 111(12):5477-5485.
［12］Gu LJ, Li J, Xue HL, Tang JY, Chen J, Zhao HJ, et al. Analysis of therapeutic effectiveness in 158 childhood acute lymphoblastic leukemia patients treated with ALL-XH-99 protocol(in Chinese)［J］. Chin J Hematol, 2004, 25(1):1-4.
［13］Campana D. Status of minimal residual disease testing in childhood haematological malignancies ［J］. Br J Haematol, 2008, 43(4):481-489.
［14］Sandlund JT, Harrison PL, Rivera G, Behm FG, Head D, Boyett J, et al. Persistence of lymphoblasts in bone marrow on day 15 and day 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia ［J］. Blood, 2002, 100(1): 43-47.
